ADVL1515 - Lilly: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors

Project: Research project

Project Details

StatusFinished
Effective start/end date4/1/175/4/20

Funding

  • Children's Hospital of Philadelphia
  • Eli Lilly and Company